SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer

SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer

Abstract Background Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherapy (SABR) delivered in just 5-fractions. Based on the...

Full description

Bibliographic Details
Main Authors: Elisha Fredman, Oded Icht, Assaf Moore, Dimitri Bragilovski, Jonathan Kindler, Shay Golan, Dror Limon
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Cancer
Subjects:
Prostate cancer
Stereotactic radiotherapy
SABR
Hydrogel spacer
Clinical trial
Online Access:https://doi.org/10.1186/s12885-024-12165-1

Internet

https://doi.org/10.1186/s12885-024-12165-1

Similar Items